Tolmar Pharmaceuticals maintains a complete inventory of Eligard (leuprolide acetate), its therapy for advanced prostate cancer, and had increased production in response to reports of shortages of other leuprolide acetate products in the U.S., the company announced. As of Aug. 25, the U.S. Food and Drug Administration listed three formulations of Lupron Depot (leuprolide acetate) as unavailable and/or on backorder for an unknown duration on the administration’s drug shortage information database. “Tolmar is pleased to…
You must be logged in to read/download the full post.
The post Tolmar Affirms Full Supply of Eligard for Palliative Treatment of Prostate Cancer appeared first on BioNewsFeeds.